Nath Bio-Genes (NATHBIOGEN)

Score breakdown: P/E: 3/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• P/B of 0.50 means the stock trades at half its book value, offering a classic Graham-style margin of safety.
• Low debt: Debt/Equity of 0.23, so the balance sheet is not stretched.
• Promoter holding of 45.60% aligns management interests with minority shareholders.
• Sales growth of 78.90% shows strong demand traction for the products.
• Modest dividend yield of 1.33% provides some income while waiting for a recovery.

Concerns

• Profit growth of -107.92% is alarming; latest quarterly net profit of ₹2 Cr on ₹66 Cr sales implies a very thin margin.
• Piotroski F-Score of 4/9 suggests weak financial health and possible operational deterioration.
• ROE of 8.13% and ROCE of 6.96% are low, indicating the business lacks a strong moat or pricing power.
• Agricultural products are inherently cyclical; high sales growth may not translate into durable profits.

AI Analysis

Let me look at Nath Bio-Genes with a value investor's discipline. The first thing that catches my eye is not earnings, but the balance sheet. The stock trades at ₹171 against book value of ₹341.05—a price-to-book of 0.50. That means I can buy a rupee of net assets for 50 paise. Graham would call that margin of safety, provided the assets are genuine and the business does not burn value. Debt is modest at 0.23 times equity, and promoter holding is 45.60%, which aligns them with public shareholders. A dividend yield of 1.33% confirms a small return even while waiting. But value investing cannot ignore economics. The P/E of 7.32 looks attractive, yet a Piotroski F-score of 4/9 tells me financial health is poor. Sales grew 78.90%, which sounds exciting, but profit growth is -107.92%—that is not a small wobble. In the latest quarter, sales were ₹66 Cr and net profit just ₹2 Cr, an operating margin of roughly 3%. This is a low-margin, capital-intensive agricultural input business. The return on equity of 8.13% and ROCE of 6.96% are uninspiring; the company is not compounding wealth at a high clip. For a seeds/agri-products company, cycles are real. Favorable conditions can drive sales, but when conditions turn, inventory and receivables hurt. The high sales growth with collapsing profit suggests we may be seeing a cyclical uptick that has not yet translated to bottom-line health. Would I buy today? It is possible to make money if this is a genuine cyclical recovery. But I need proof of sustained profitability, not just asset backing. I will watch gross margins, working capital, and whether quarterly profit improves from ₹2 Cr. The safety net of book value is strong, but a weak F-score demands caution. I am interested, not yet enthusiastic.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer